Quick Answer
TriSalus Life Sciences, Inc. reported Operating Income of -$26.95 million for fiscal year 2025.
TriSalus Life Sciences, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$26.95M | +25.5% |
| 2024 | -$36.16M | +33.6% |
| 2023 | -$54.48M | -49.5% |
| 2022 | -$36.44M | -1098.4% |
| 2021 | -$3.04M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$9.01M | -3.1% | -22.9% |
| June 30, 2025 | -$7.33M | +10.3% | -0.0% |
| March 31, 2025 | -$7.33M | +37.2% | +16.1% |
| September 30, 2024 | -$8.74M | +53.1% | -6.9% |
| June 30, 2024 | -$8.17M | +28.5% | +30.0% |
| March 31, 2024 | -$11.67M | -15.3% | +37.3% |
| September 30, 2023 | -$18.62M | -129.5% | -62.8% |
| June 30, 2023 | -$11.43M | -3866.4% | -13.0% |
- TriSalus Life Sciences, Inc. showed an increase of +25.5% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, TriSalus Life Sciences, Inc.’s operating income has declined by 786.2% (from -$3.04 million to -$26.95 million).
- The most recent figure is from TriSalus Life Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: